Overview

An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of decitabine in the treatment of myelodysplastic syndrome (name of a group of conditions that occur when the blood-forming cells in the bone marrow are damaged) in Chinese patients.
Phase:
Phase 3
Details
Lead Sponsor:
Xian-Janssen Pharmaceutical Ltd.
Treatments:
Azacitidine
Decitabine